Drugs and Pharmaceuticals, Medical

Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft Tissue Sarcoma (ASCO 2010)

Author: Epeius Biotechnologies Corporation
Dateline: San Marino, California (SAN MARINO, Calif.)  | Tue, 01 Jun 2010

freeNewsArticles Story Summary: “SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announces the results of the clinical trial entitled 'Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma' at the ASCO Annual Meeting on June 8, 2010. The presentation will be discussed by Dr. Kristen N. Ganjoo, Stanford University Medical Center, Palo Alto CA.”



A R T I C L E:

Epeius Biotechnologies Corporation (www.epeiusbiotech.com) today announces the results of the clinical trial entitled "Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma" at the ASCO Annual Meeting on June 8, 2010. The presentation will be discussed by Dr. Kristen N. Ganjoo, Stanford University Medical Center, Palo Alto CA.

STUDY SUMMARY: The goals of the study were to evaluate the over-all safety and efficacy of intravenous infusions of Rexin-G, a tumor-targeted retrovector bearing a cytocidal anti-cyclin G1 construct, in chemo-therapy-resistant bone and soft tissue sarcoma. A Phase II "run-in" component was integrated by adaptive design by continuing treatment if the patient had Grade 1 or less toxicity. Thirty-six patients received escalating doses of Rexin-G intravenously three times a week for four weeks. Analysis of safety showed no dose-limiting toxicity and no cumulative toxicity in patients treated with Rexin-G monotherapy for up to 2 years. Analysis of efficacy revealed a dose-dependent relationship between progression-free survival/overall survival and Rexin-G dosage (p = 0.02 and 0.002 respectively) which was significant at the 5% statistical level by the log-rank test. Median survival was 11.5 months and one-year survival was 40% in the high-dose groups. These findings indicate that intravenous Rexin-G is safe and well-tolerated with no cumulative toxicity, and that Rexin-G controls tumor growth, and prolongs progression-free survival and over-all survival times in a dose-dependent manner in patients with chemotherapy resistant bone and soft tissue sarcoma.

About Epeius Biotechnologies:

Epeius Biotechnologies Corporation (www.epeiusbiotech.com) is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its lead products, Rexin-G® and Reximmune-C, and its high-performance gene delivery systems.

To learn more about these agents and/or ongoing clinical trials, please contact Dr. Erlinda M. Gordon at egordon_@_epeiusbiotech.com.

###


Copyright © 2010 by Epeius Biotechnologies Corporation and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

• Web Image (72dpi): https://www.send2press.com/mediaboom/10-0504-epeiusbio_72dpi.jpg

Story Title: Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft Tissue Sarcoma (ASCO 2010)
• REFERENCE KEYWORDS/TERMS: Intravenous Rexin-G, San Marino, California, ASCO Annual Meeting, Drugs and Pharmaceuticals, Medical, , SAN MARINO, Calif..

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Epeius Biotechnologies Corporation); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Tue, 01 Jun 2010 12:29:15 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.
Medical

Tumor-targeted Rexin-G Prolongs Survival in Gemcitabine-resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010)

Author: Epeius Biotechnologies Corporation
Dateline: San Marino, California (SAN MARINO, Calif.)  | Mon, 24 May 2010

freeNewsArticles Story Summary: “SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announces the results of the clinical study entitled 'Phase I and II Studies of Intravenous Rexin-G as Monotherapy for Gemcitabine-resistant Metastatic Pancreas Cancer' at the ASCO Annual Meeting on June 6, 2010. The presentation will be discussed by Dr. Howard W. Bruckner, Bruckner Oncology, New York, NY.”



A R T I C L E:

Epeius Biotechnologies Corporation (www.epeiusbiotech.com) today announces the results of the clinical study entitled "Phase I and II Studies of Intravenous Rexin-G as Monotherapy for Gemcitabine-resistant Metastatic Pancreas Cancer" at the ASCO Annual Meeting on June 6, 2010. The presentation will be discussed by Dr. Howard W. Bruckner, Bruckner Oncology, New York, NY.

STUDY SUMMARY: The goals of the Phase I/II study were to evaluate the over-all safety and efficacy of intravenous infusions of Rexin-G, a tumor-targeted retrovector bearing a cytocidal anti-cyclin G1 construct, in gemcitabine-resistant pancreas cancer. A Phase II "run in" study was integrated by adaptive design wherein additional cycles were given if the patient had Grade 1 or less toxicity. Twenty patients received escalating doses of Rexin-G intravenously three times a week for four weeks. Analysis of safety showed no dose-limiting toxicity and no cumulative toxicity in patients treated up to 18 months. Analysis of efficacy in evaluable patients revealed significant tumor responses: 100% tumor control rate (TCR) was observed at all doses tested, and 24% partial response (PR) or complete response (CR) by RECIST criteria in the high dose cohorts. A dose-dependent relationship between overall survival and Rexin-G dosage was demonstrated, which was significant at the 5% statistical level by log rank test (p = 0.03). Median survival was 9.3 months and one-year survival was 33% in the high dose groups. Remarkably, one patient exhibited a complete response with the (adaptive) repeated cycles, attaining clinical remission after 9 months of continued treatment with Rexin-G. These findings indicate that intravenous Rexin-G is safe and well-tolerated with no cumulative toxicity and that Rexin-G controls tumor growth and may prolong over-all survival in a dose-dependent manner in patients with gemcitabine-resistant pancreas cancer.

About Epeius Biotechnologies:

Epeius Biotechnologies Corporation (www.epeiusbiotech.com) is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its lead products, Rexin-G and Reximmune-C, and its high-performance gene delivery systems. To learn more about these agents and/or ongoing clinical trials, please contact Dr. Erlinda M. Gordon at egordon @ epeiusbiotech.com .

###


Copyright © 2010 by Epeius Biotechnologies Corporation and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

• Web Image (72dpi): https://www.send2press.com/mediaboom/10-0504-epeiusbio_72dpi.jpg

Story Title: Tumor-targeted Rexin-G Prolongs Survival in Gemcitabine-resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010)
• REFERENCE KEYWORDS/TERMS: gene delivery systems, San Marino, California, ASCO 2010, Devices and Research, Medical, , SAN MARINO, Calif..

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Epeius Biotechnologies Corporation); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Mon, 24 May 2010 18:44:14 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.
Drugs and Pharmaceuticals, Medical

Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010)

Author: Epeius Biotechnologies Corporation
Dateline: San Marino, California (SAN MARINO, Calif.)  | Mon, 24 May 2010

freeNewsArticles Story Summary: “SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announces the clinical results of the study entitled 'A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol' at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, and Principal Investigator of the study.”



A R T I C L E:

Epeius Biotechnologies Corporation (www.epeiusbiotech.com) today announces the clinical results of the study entitled "A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol" at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, and Principal Investigator of the study.

SUMMARY: Rexin-G and Reximmune-C are tumor-targeted retrovectors bearing a cytocidal anti-cyclin G1 construct and a controllable GM-CSF expression construct, respectively. The working hypothesis underlying this two-tier complementary approach to tumor eradication and cancer vaccination is that a personalized vaccination of a patient against his or her own specific cancer can be achieved by combining (1) a targeted vector bearing a tumoricidal payload, i.e. Rexin-G, with (2) a targeted vector bearing a potent immuno-stimulatory (GM-CSF) gene, i.e. Reximmune-C. In this model, Rexin-G is first administered to control tumor growth and expose neoantigens within the tumor microenvironment, followed by defined pulses of Reximmune-C, intended to recruit the patient's immune cells into these lesions, thereby prompting immunologic activation, recognition of tumor neoantigens, and induction of a beneficial antitumor immunity. The initial results of a Phase I/II dose escalation study showed that, in addition to the expected tumoricidal effects of Rexin-G, histopathologic examination of biopsied tumors from patients with a diversity of cancer types revealed targeted nanoparticle delivery, GM-CSF transgene expression, and localized immune responses within the lesions. Importantly, no circulating GM-CSF protein was detected and no dose limiting toxicity was observed throughout the treatment period. Moreover, there appears to be a significant survival benefit which suggests that this two-tier approach has considerable merit as a therapeutic vaccine.

About Epeius Biotechnologies:

Epeius Biotechnologies Corporation (www.epeiusbiotech.com) is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its lead products, Rexin-G and Reximmune-C, and its high-performance gene delivery systems. To learn more about these agents and/or ongoing clinical trials, please contact Dr. Erlinda M. Gordon at egordon @ epeiusbiotech.com .

###


Copyright © 2010 by Epeius Biotechnologies Corporation and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

• Web Image (72dpi): https://www.send2press.com/mediaboom/10-0504-epeiusbio_72dpi.jpg

Story Title: Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010)
• REFERENCE KEYWORDS/TERMS: Reximmune-C for Cancer Immunotherapy, San Marino, California, GeneVieve Protocol, Drugs and Pharmaceuticals, Medical, , SAN MARINO, Calif..

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Epeius Biotechnologies Corporation); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Mon, 24 May 2010 13:06:41 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.
Medical, Medical and Health Products

ContinuLink Health Technologies, A Leader in Web-based Home Care Software Announces Integration with Cardiocom

Author: ContinuLink Health Technologies
Dateline: Atlanta, Georgia (ATLANTA, Ga.)  | Thu, 13 May 2010

freeNewsArticles Story Summary: “ATLANTA, Ga. -- ContinuLink, a leader in Web-based home care software has announced that it has entered into a business development relationship with Cardiocom to provide a two way interface between Cardiocom's Omnivisor Pro software application and the Web-based ContinuLink application. Cardiocom is a developer, manufacturer and clinical service provider of award-winning telehealth solutions.”



A R T I C L E:

ContinuLink, a leader in Web-based home care software has announced that it has entered into a business development relationship with Cardiocom to provide a two way interface between Cardiocom's Omnivisor Pro software application and the Web-based ContinuLink application. Cardiocom is a developer, manufacturer and clinical service provider of award-winning telehealth solutions.

ContinuLink is the first joint customer to actively implement this dynamic interface tool. Cardiocom's telehealth system provides a unique opportunity to proactively manage and customize the patient care. Every day patients use the Cardiocom Commander Telehealth System to communicate with a participating telehealth nurse. The Commander Home Telemonitoring System guides the patient through an interactive health check and collection of vital signs including; weight, blood pressure, oxygen saturation and heart rate. This information is immediately available for review via a standard phone line or a cellular transmission to the agency's telehealth department.

The two way interface allows demographic data to flow from the ContinuLink application once a patient is enrolled in telehealth. In addition, all users of ContinuLink, namely field staff will now to be able to have access to daily transmitted vital sign data, symptomatic information and clinical notes written by the telehealth nurse. The access to this critical data is pertinent because it allows field staff to make better decisions based on previously transmitted information, significantly improving the time it takes to make timely interventions, such as medication adjustments.

"The best way for us to continue to provide outstanding service to our customers is to integrate our software with award-winning companies in the industry," said Satish Movva, CEO of ContinuLink. "Cardiocom is a leader in helping home care agencies improve their outcomes and increasing clinical efficiencies at the same time. Changes in Health Care Reform in 2010 means agencies are looking even more closely at reducing acute care hospitalization rates for patients with chronic diseases."

"Cardiocom is known for providing innovative telehealth solutions that aid our customers in achieving their clinical goals," said Daniel L. Cosentino, CEO and President of Cardiocom. "We are delighted to be partnering with ContinuLink. ContinuLink is a premier home care software company that is strategically positioned for significant growth."

About ContinuLink:

ContinuLink, Your Link to The Continuum of Care(TM), is a software solution for health care businesses including Home Health Care, Hospice, Private Duty, and Supplemental Medical Staffing. With its reliance on open Web technologies, ContinuLink is well ahead of any other software in the industry. Always available anywhere, anytime, ContinuLink not only makes sense, it makes dollars and sense. For more information please visit www.continulink.com or call 561-339-9950.

About Cardiocom:

Cardiocom(R), the Experts in Telehealth(SM), is an award-winning leader in innovative home telehealth solutions. Founded in 1997, Cardiocom develops, manufactures and markets its own telehealth devices for heart failure, diabetes, hypertension, COPD, asthma and other chronic conditions. Cardiocom's clients include some of the most respected home health groups, health plans, hospitals, physician groups, and coordinated care companies in the nation. Through these established relationships, Cardiocom improves the lives of thousands of people each day. For more information on Cardiocom and its services, visit www.cardiocom.com or call 888-243-8881.

###


Copyright © 2010 by ContinuLink Health Technologies and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

• Web Image (72dpi): https://www.send2press.com/mediaboom/10-0513-continulink_72dpi.jpg

Story Title: ContinuLink Health Technologies, A Leader in Web-based Home Care Software Announces Integration with Cardiocom
• REFERENCE KEYWORDS/TERMS: ContinuLink healthcare SaaS, Atlanta, Georgia, Cardiocom Telehealth, Medical and Health Products, Medical, , ATLANTA, Ga..

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (ContinuLink Health Technologies); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Thu, 13 May 2010 13:04:39 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.
Medical

Interim HealthCare Honors Moms with Unique Mother’s Day E-cards

Author: Interim HealthCare Inc.
Dateline: Sunrise, Florida (SUNRISE, Fla.)  | Wed, 05 May 2010

freeNewsArticles Story Summary: “SUNRISE, Fla. -- This Mother's Day, Interim HealthCare Inc., the nation's largest and oldest franchise healthcare company, is recognizing moms across the country with unique Mother's Day e-cards. The e-cards allow users to share their favorite stories about their mothers and create a customized flower in her honor.”



A R T I C L E:

This Mother's Day, Interim HealthCare Inc., the nation's largest and oldest franchise healthcare company, is recognizing moms across the country with unique Mother's Day e-cards.

The e-cards - which can be customized online at www.interimhealthcare.com/garden - allow users to share their favorite stories about their mothers and create a customized flower in her honor. Each specially designed flower is then "planted" on the website's Mother's Day virtual flower garden which will be in bloom for the month of May.

"This Mother's Day, Interim HealthCare is honoring all the moms out there for doing one of the hardest jobs in the world," said Kathleen Gilmartin, President and CEO of Interim HealthCare Inc. "Similar to moms, Interim HealthCare is about caring, compassion and trust, and creating an e-card is a great way to thank her for all her hard work on her special day."

The Mother's Day e-card initiative was created by Interim HealthCare to recognize moms for all of their hard work. Interim HealthCare is the leading health care franchise company providing home health care and medical staffing provider. Through home care and health care staffing, Interim HealthCare professionals provide care and compassion to nearly 50,000 people on any given day.

"During these difficult economic times, families are looking for ways to save while still celebrating special holidays such as Mother's Day," said Gilmartin. "Our Interim HealthCare e-cards are free, fun, easy to create for both kids and adults, and a meaningful way to honor your mom."

About Interim HealthCare:

Founded in 1966, Interim HealthCare® is the nation's oldest proprietary national health care franchise organization providing health care personnel at all skill levels in all settings. Through a comprehensive network of more than 300 independently owned franchise offices, Interim HealthCare® franchisees are the largest combined provider of community-based home care (skilled and non-medical) and health care staffing. Interim HealthCare is unique in combining the commitment of local ownership with the support of a national organization that develops innovative programs and quality standards that improve the delivery of service through franchisees who employ more than 75,000 health care workers who serve 50,000 people each day. For more information or to locate an Interim HealthCare office, visit www.interimhealthcare.com .

Franchise opportunities are available throughout the country for candidates interested in joining the country's largest and oldest franchise healthcare company. Qualified candidates should possess a minimum net worth of $400,000, and a minimum liquidity of $50,000. Franchisees can expect their initial investment to range from approximately $115,500 to $188,500 including the franchise fee. Additional franchise information is available at www.interimfranchising.com .

###


Copyright © 2010 by Interim HealthCare Inc. and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

• Web Image (72dpi): https://www.send2press.com/mediaboom/10-0505-interimhc_72dpi.jpg

Story Title: Interim HealthCare Honors Moms with Unique Mother's Day E-cards
• REFERENCE KEYWORDS/TERMS: health care staffing, Sunrise, Florida, home care franchise, Medical, Health, , SUNRISE, Fla..

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Interim HealthCare Inc.); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Wed, 05 May 2010 17:42:52 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.
Drugs and Pharmaceuticals, Medical

Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy

Author: Epeius Biotechnologies Corporation
Dateline: San Marino, California (SAN MARINO, Calif.)  | Tue, 04 May 2010

freeNewsArticles Story Summary: “SAN MARINO, Calif. -- Epeius Biotechnologies Corporation, a leader in the field of targeted genetic medicine, reports the publication of three major publications in the field. The first article entitled 'Rexin-G, A Targeted Genetic Medicine for Metastatic Cancer' (Expert Opinion on Biological Therapy, May, 2010) documents the development of Rexin-G: a tumor-targeted retrovector bearing a cytocidal cyclin G1 construct; the first targeted gene therapy vector to gain FDA Fast Track designation and Orphan Drug priorities for multiple cancer indications in the USA.”



A R T I C L E:

Epeius Biotechnologies Corporation, a leader in the field of targeted genetic medicine, reports the publication of three major publications in the field. The first article entitled "Rexin-G, A Targeted Genetic Medicine for Metastatic Cancer" (Expert Opinion on Biological Therapy, May, 2010) documents the development of Rexin-G: a tumor-targeted retrovector bearing a cytocidal cyclin G1 construct; the first targeted gene therapy vector to gain FDA Fast Track designation and Orphan Drug priorities for multiple cancer indications in the USA. What the reader will gain: In recording the development of Rexin-G as a novel targeted biological therapy, this review also highlights important aspects of vector engineering which served to overcome the physiological barriers to gene delivery as it addresses the key regulatory issues involved in the development of a targeted gene therapy product. Take home message: Progressive clinical development of Rexin-G demonstrates the potential safety and efficacy of targeted genetic medicine in otherwise intractable cancers, while validating the design engineering of the molecular biotechnology platform.

The second article, entitled "Noteworthy Clinical Case Studies in Cancer Gene Therapy" (Intl. J. Oncology, April, 2010) highlights important aspects of Rexin-G bio-pharmacology, as this tumor-targeted vector advances as an efficacious anti-cancer agent. What the reader will gain: These remarkable case studies, in and of themselves, reveal important aspects of the molecular pharmacology, advanced clinical protocols, refinement of patient monitoring, expanding treatment options, and strategic medical approaches to patient care that exemplify and thereby extend the established principles of pathotropic targeting and cancer gene therapy to a new generation of clinical practitioners. Take home message: Each case study, in an otherwise intractable cancer, "teaches" a vital lesson in the emerging praxis of cancer control.

Finally, the third article comes in the form of a Mini review entitled "Nanoparticles and the Immune System" (Endocrinology, Feb, 2010) co-authored by members of the FDA Center for Drug Evaluation and Research, Office of Pharmaceutical Science, and the Nanotechnology Characterization Laboratory of the National Cancer Institute. What the reader will gain: This astute review of medical nanotechnology aptly describes the concept of targeted delivery of Rexin-G followed by Reximmune-C as a two-tier complementary approach aimed at both tumor eradication and personalized cancer vaccination. That is, the first step involves the use of Rexin-G to target and control the progression of metastatic cancer, whereas the second step employs Reximmune-C to induce a localized cancer immunization. Take home message: This is a commendable and timely review of these first-in-class, best-in-class tumor-targeted anti-cancer agents, which may supersede more cumbersome approaches to personalized cancer vaccinations.

About Epeius Biotechnologies:

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems. To learn more about our recent publications and/or proprietary biotechnologies, please visit www.epeiusbiotech.com .

###


Copyright © 2010 by Epeius Biotechnologies Corporation and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

• Web Image (72dpi): https://www.send2press.com/mediaboom/10-0504-epeiusbio_72dpi.jpg

Story Title: Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy
• REFERENCE KEYWORDS/TERMS: targeted genetic medicines, San Marino, California, Metastatic Cancer Research, Drugs and Pharmaceuticals, Medical, , SAN MARINO, Calif..

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Epeius Biotechnologies Corporation); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Tue, 04 May 2010 12:06:12 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.
Fertility and IVF, Medical

Sher Institute Donating Free IVF Treatments at Upcoming Seminars – Mother’s Day Donations Part of ‘Giving Back’ Program

Author: Sher Institute for Reproductive Medicine
Dateline: Las Vegas, Nevada (LAS VEGAS, Nev.)  | Tue, 20 Apr 2010

freeNewsArticles Story Summary: “LAS VEGAS, Nev. -- Sher Institute for Reproductive Medicine (SIRM) is donating free In-Vitro Fertilization (IVF) treatments at upcoming fertility education seminars on May 11 and 12, in celebration of Mother's Day on May 9, 2010. The donated treatment cycles are part of the Sher Institute 'Giving Back' Program.”



A R T I C L E:

Sher Institute for Reproductive Medicine (SIRM) is donating free In-Vitro Fertilization (IVF) treatments at upcoming fertility education seminars on May 11 and 12, in celebration of Mother's Day on May 9.

The donated treatment cycles are part of the Sher Institute "Giving Back" Program. The Giving Back Program includes these initiatives and many more:

* Donation of two IVF cycles at Las Vegas seminars - An IVF cycle costs on average around $10,000.
* Donation of IVF cycles to four attendees at educational seminars in Dallas and New Jersey in March, 2010.
* Offering discounted egg freezing for cancer patients through Fertile Hope's "Sharing Hope" program.
* Hosting free, infertility seminars at SIRM locations throughout the country.

"Given the economic challenges many families are facing, my colleagues and I are struck by the number of patients who come to see us seeking treatment only to learn that the cost is beyond their reach," SIRM Founder and Executive Medical Director Geoffrey Sher, M.D. said.

Las Vegans continue to bear the brunt of the national economic downturn. The major industries have yet to rebound and the unemployment rate is the second highest in the nation.

"We live and work here and we see first hand how many patients need treatment but can't afford it, especially now," said SIRM Las Vegas Medical Director Jeffrey Fisch, M.D. "We want to offer our resources and expertise to help our community."

Helping patients gain access to treatment has long been a driving philosophy of the Sher Institute. During the last three decades, Dr. Sher and the Sher Institute have donated hundreds of free treatments to patients and couples from all over the country.

About the Sher Institute for Reproductive Medicine(R) (SIRM(R)):

The Sher Institute for Reproductive Medicine is a national network of fertility clinics specializing in cutting-edge technology, personalized treatment and compassionate care. SIRM Founder Dr. Geoffrey Sher established the first private In Vitro Fertilization (IVF) program in the United States. Dr. Sher and his colleagues have been influential in the development of dozens of important breakthroughs in the field of reproductive care.

More information about the Sher Institute for Reproductive Medicine: www.haveababy.com .

###


Copyright © 2010 by Sher Institute for Reproductive Medicine and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

• Web Image (72dpi): https://www.send2press.com/mediaboom/10-0323-sirmed_72dpi.jpg

Story Title: Sher Institute Donating Free IVF Treatments at Upcoming Seminars - Mother's Day Donations Part of 'Giving Back' Program
• REFERENCE KEYWORDS/TERMS: In-Vitro Fertilization, Las Vegas, Nevada, Reproductive Medicine, Fertility and IVF, Medical, , LAS VEGAS, Nev..

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Sher Institute for Reproductive Medicine); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Tue, 20 Apr 2010 17:02:28 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.
Medical, Ophthalmology and Vision

Topcon Introduces EyeRoute Mobile, First iPhone Application for Ophthalmic Image Management

Author: Topcon Medical Systems, Inc.
Dateline: Paramus, New Jersey (PARAMUS, N.J.)  | Thu, 08 Apr 2010

freeNewsArticles Story Summary: “PARAMUS, N.J. -- Topcon Medical Systems announced today that the mobile version of its successful EyeRoute(R) Image Management Suite is now available as a dedicated iPhone application from the Apple(R) iTunes store in North America. First presented in October 2009 at the American Academy of Ophthalmology Meeting in San Francisco, EyeRoute Mobile sets the stage for connectivity on the go.”



A R T I C L E:

Topcon Medical Systems announced today that the mobile version of its successful EyeRoute® Image Management Suite is now available as a dedicated iPhone application from the Apple® iTunes store in North America. First presented in October 2009 at the American Academy of Ophthalmology Meeting in San Francisco, EyeRoute Mobile sets the stage for connectivity on the go.

Ophthalmologists who have incorporated the EyeRoute in their practice, can now securely access images and reports from any 3GS-compatible iPhone, iPod touch, or iPad, via EyeRoute Mobile even when out of the clinic, from anywhere Internet connectivity is available.

Using the EyeRoute® Mobile's intuitive touch screen, patient images stored in EyeRoute can be listed by modality or visit date, and reviewed, panned, zoomed, enhanced, and annotated with text and audio dictation options. Once reviewed, a smart integrated messaging system allows users to share information with other EyeRoute users through the network.

Dr. Julia Haller, MD, Ophthalmologist-in-Chief at Wills Eye Hospital, among the very first users of the EyeRoute® Mobile, states that, "I view this new addition to the EyeRoute suite as a veritable boon in enabling practitioners to stay connected wherever they are in the world. Now, more than ever before, with Topcon's EyeRoute iPhone application all members of the Wills Eye network, including those working in, remote areas can connect with our EyeRoute patient database on-the-go."

The EyeRoute® Mobile application can be downloaded from the Apple iTunes store, at an attractive early adopter price of $19.99 for the first year. Even users who currently do not utilize EyeRoute in their practice still gain access to an extensive demo database of images and pathologies and the various viewing and editing features. Customers who utilize EyeRoute in their practice can then activate the link to the mobile application and gain access to their own EyeRoute database. A 3GS-compatible iPhone with an OS 3.0 provides optimal performance and is recommended for integration with EyeRoute Mobile.

"In our quest to provide practitioners with enhanced diagnostic solutions, at Topcon Medical we believe that the integration of EyeRoute with the iPhone will enable eye care professionals to achieve greater workflow efficiencies and benefit both practitioners and patients with significant time and cost savings owing to its virtually anywhere, anytime access for quick reference," says Katrin Teigeler, VP of Marketing at Topcon.

About EyeRoute Image Management Suite:

The EyeRoute Ophthalmic Image Management System integrates images and reports from Topcon and over 100 other manufacturers' systems into a single, secure, digital environment. With the ability to view, compare, annotate and transmit patient images seamlessly, EyeRoute provides for fluent workflow efficiency and helps the transition to a paperless environment. The web-browser based system allows for rapid access to patient information, anytime, from virtually anywhere, including workstations, remote computers or even the iPhone. Designed as a scalable and flexible solution, EyeRoute integrates with most EMR's, is fully standards compliant (DICOM, HL7) and scalable to fit practices today and tomorrow.

About Topcon Medical Systems, Inc.:

Topcon Medical Systems, Inc. ( TMS - www.topconmedical.com/products/eyeroutemobile.htm ) is a market leader in diagnostic imaging technologies and connectivity solutions for ophthalmology. For over 35 years, TMS has been developing and manufacturing state-of-the-art instrumentation, including the first 3D-OCT system, a wide range of mydriatic and non-mydriatic digital fundus cameras, slit lamps, autorefractors and keratometers. TMS' EyeRoute® Image Management System allows for the seamless integration of Topcon's and other manufacturers' devices. Based in Paramus, NJ, TMS is responsible for the entire Americas region, including dealer sales, corporate accounts and is also headquarters of the Advanced Technology Products Division. TMS is a division of Topcon America Corporation, a wholly owned subsidiary of Topcon Corporation of Tokyo, Japan.

More information: www.topcon.com .

Apple®, iTunes®, iPhone®, iPod touch® and iPad™ are trademarks of Apple, Inc. EyeRoute® is a registered trademark of Topcon.

###


Copyright © 2010 by Topcon Medical Systems, Inc. and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

• Web Image (72dpi): https://www.send2press.com/mediaboom/10-0408-eyeroute_72dpi.jpg

Story Title: Topcon Introduces EyeRoute Mobile, First iPhone Application for Ophthalmic Image Management
• REFERENCE KEYWORDS/TERMS: EyeRoute Image Management Suite, Paramus, New Jersey, ophthalmology diagnostic imaging, Ophthalmology and Vision, Medical, , PARAMUS, N.J..

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Topcon Medical Systems, Inc.); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Thu, 08 Apr 2010 08:58:46 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.
Advertising and Marketing, Medical

Eularis Updates Reports That Help Pharmaceutical Companies Do More for Real Growth Than Simply Downsizing

Author: Eularis
Dateline: London, England (LONDON, U.K.)  | Mon, 05 Apr 2010

freeNewsArticles Story Summary: “LONDON, U.K. -- The pharmaceutical industry is facing unprecedented challenges on many fronts - a slew of patient expiries, a lack of blockbusters in the pipeline to replace the patent expiries, decreasing growth in many major markets, generic competition, constantly changing regulatory and competitive environment rendering old tools for analysis obsolete, increased pressure on CEOs to deliver shareholder growth resulting in budget cuts, downsizing, and less than optimal results.”



A R T I C L E:

The pharmaceutical industry is facing unprecedented challenges on many fronts - a slew of patient expiries, a lack of blockbusters in the pipeline to replace the patent expiries, decreasing growth in many major markets, generic competition, constantly changing regulatory and competitive environment rendering old tools for analysis obsolete, increased pressure on CEOs to deliver shareholder growth resulting in budget cuts, downsizing, and less than optimal results.

Therefore, given these challenges, today is the worst time in the history of pharmaceuticals to be a pharmaceutical marketer.

Eularis has updated its reports that focus on specific key issues for pharma marketers that help them understand how to handle these specific situations. These reports uncover practices to predict how and where pharmaceutical marketing and sales investments will yield the highest market share and market share price and highlight real life case studies.

Readers will benefit from the step-by-step guidelines on successfully implementing approaches for real and measurable results available only in these reports.

Details about these updated reports can be found at:

www.ePharmaROI.com : How to Harness the Power of Social Media in Pharmaceutical eMarketing.

www.pharmaprelaunchroi.com : Pre-Launch Planning: Priming your Pharmaceutical Brand for Profit and Success.

www.GenericsDefenseStrategies.com : How to Plan an Effective Generics Defense Strategy: Planning, Tactics and Implementation.

www.PatientAdherenceROI.com : Ensuring Profitable Patient Adherence Programs: Using Analytics and Metrics to Improve the Bottom Line

www.PharmaIndustrySFE.com : Pharmaceutical Sales Force Effectiveness Metrics: Are You Measuring the Wrong Things?

www.PharmaMarketingROI.com : Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics and Metrics to Improve the Bottom Line.

www.epharmaroi.com : How To Harness The Power Of Social Media In Pharmaceutical eMarketing.

About Eularis:

Eularis provides sophisticated pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches, whose reliance on historical or analogue data reduces their accuracy, Eularis' proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps pharmaceutical marketing teams to quickly plan, measure, validate and optimize their sales and marketing performance.

The company has developed significant experience in the global pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

For more information about Eularis, visit www.eularis.com .

###


Copyright © 2010 by Eularis and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

• Web Image (72dpi): https://www.send2press.com/mediaboom/10-0405-eularis_72dpi.jpg

Story Title: Eularis Updates Reports That Help Pharmaceutical Companies Do More for Real Growth Than Simply Downsizing
• REFERENCE KEYWORDS/TERMS: Eularis, London, England, pharmaceutical analytics, Advertising and Marketing, Medical, , LONDON, U.K..

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Eularis); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Mon, 05 Apr 2010 13:58:19 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.
Medical

Breathe California Announces State-Wide Media Call on Tuberculosis for World TB Day

Author: Breathe California
Dateline: San Jose, California Mon, 22 Mar 2010

freeNewsArticles Story Summary: “SAN JOSE, Calif. -- Tuberculosis (TB) is still a global and local threat. Hear the latest global, U.S., California, and local trends in TB, and recommendations from the experts. Breathe California is hosting a state-wide Media Call on Tuberculosis on Tuesday, March 23, 10:30 a.m. PDT. March 24th is World TB Day.”



A R T I C L E:

SAN JOSE, Calif. /Neotrope News Network/ -- Tuberculosis (TB) is still a global and local threat. Hear the latest global, U.S., California, and local trends in TB, and recommendations from the experts. Breathe California is hosting a state-wide Media Call on Tuberculosis on Tuesday, March 23, 10:30 a.m. PDT. March 24th is World TB Day.

For the call-in, speakers include: Ernesto Jaramillo, World Health Organization Technical Officer; James Watt, M.D., M.P.H., California State TB Controller; Frank Alvarez, M.D., M.P.H., Los Angeles County TB Controller; and Rachel Orduno, former TB Patient and Patient Activist with TB PhotoVoice project (tbphotovoice.org/tbpv2/).

Threats to continued adequate funding jeopardize the maintenance of the infrastructure needed to keep the numbers low and to drive them even lower in our fight to control and eventually eliminate TB.

Media who wish to participate, Call in # is 1-877-578-0255, Conference ID #: 61200439.

Sponsor: RESULTS Educational Fund; Hosts: California TB Controllers Association and Breathe California (www.lungsrus.org).

###


Copyright © 2010 by Breathe California and Send2Press® Newswire, a service of Neotrope® - all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

• Web Image (72dpi): https://www.send2press.com/mediaboom/10-0322-breathcal_72dpi.jpg

Story Title: Breathe California Announces State-Wide Media Call on Tuberculosis for World TB Day
• REFERENCE KEYWORDS/TERMS: Breathe California, San Jose, California, World TB Day, Medical, Health, , .

IMPORTANT NOTICE: some content which is considered "old" or "archival" may reference an event which has already occurred; some content possibly considered "advertorial" may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Breathe California); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Mon, 22 Mar 2010 19:09:36 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.